Clinical Practice Points
- •Various genetic alterations act as driver mutations in different lung cancers. ALK gene alterations are commonly encountered in non–small cell lung cancer, and ALK inhibitors are widely used to treat such cases. The presence of ALK mutations in neuroendocrine tumors of the lung is rare, and the literature regarding the use of ALK inhibitors in such cases is extremely limited. Even with treatment, survival of extensive-stage SCLC or LCNEC of the lung is very poor.
- •We present a case of ALK+ high–grade NET of the lung, who responded well to one of the ALK inhibitors (alectinib). The patient has survived for more than 60 months, which is rare in such extensive-stage neuroendocrine malignancy. Our case adds more evidence to the presence of ALK mutation in NETs of the lung, and treatment response to ALK inhibitors.
- •Based on our case and review of prior reports, we believe ALK inhibitors can be a viable therapeutic option in NETs of the lung in the presence of targetable ALK mutations. Larger studies analyzing ALK inhibitors use in NETs of the lung might not be achievable due to the rarity of the condition. However, with potentially efficacious treatment options available, screening for ALK genetic alterations should be considered in all cases of neuroendocrine lung tumors.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Lung Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Lung cancer genomics.Acta Med Acad. 2019; 48: 78-83https://doi.org/10.5644/ama2006-124.244
- Genomic profiling and clinicopathological characteristics of neuroendocrine tumors of the lung in East Asian Patients.In Vivo. 2020; 34: 3375-3385https://doi.org/10.21873/invivo.12176
- Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).J Clin Oncol. 2021; 39: 619-630https://doi.org/10.1200/JCO.20.01055
- Large-cell neuroendocrine carcinoma of the lung: a population-based study.Clin Lung Cancer. 2020; 21: e99-e113https://doi.org/10.1016/j.cllc.2019.07.011
- Survival and prognosis of lung large cell neuroendocrine carcinoma.Bull Cancer. 2021; 108: 981-987https://doi.org/10.1016/j.bulcan.2021.04.010
- Molecular profiling and survival of completely resected primary pulmonary neuroendocrine carcinoma.Clin Lung Cancer. 2017; 18: e197-e201https://doi.org/10.1016/j.cllc.2016.11.014
- Large cell neuroendocrine carcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement with response to alectinib.Intern Med. 2018; 57: 713-716https://doi.org/10.2169/internalmedicine.9368-17
- Use of ALK immunohistochemistry for optimal therapeutic strategy of pulmonary large-cell neuroendocrine carcinoma and identification of a novel KIF5B-ALK fusion oncokinase.Anticancer Res. 2019; 39: 413-420https://doi.org/10.21873/anticanres.13127
- ALK rearrangement in lung neuroendocrine neoplasms: case series of non-Asian patients with response to ALK inhibitors.Clin Lung Cancer. 2021; (Published online January 17S1525-730400007-3)https://doi.org/10.1016/j.cllc.2021.01.004
- Dramatic response to alectinib in an ALK-positive LCNEC patient with a poor performance status: a case report.Respirol Case Rep. 2021; 9: e0817https://doi.org/10.1002/rcr2.817
- Case report: a pregnant woman diagnosed as ALK-rearrangement lung large cell neuroendocrine cancer with brain metastasis.Front Oncol. 2022; 12823813https://doi.org/10.3389/fonc.2022.823813
- A case of metastatic atypical neuroendocrine tumor with ALK translocation and diffuse brain metastases.Oncologist. 2017; 22: 768-773https://doi.org/10.1634/theoncologist.2017-0054
- ALK-rearrangement neuroendocrine carcinoma of the lung: a comprehensive study of a rare case series and review of literature.Onco Targets Ther. 2018; 11: 4991-4998https://doi.org/10.2147/OTT.S172124
- Atypical carcinoid tumor with anaplastic lymphoma kinase (ALK) rearrangement successfully treated by an ALK inhibitor.Intern Med. 2016; 55: 3151-3153https://doi.org/10.2169/internalmedicine.55.6738
- Phenotypic variation of an ALK-positive large-cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors.Histopathology. 2018; 72: 707-710https://doi.org/10.1111/his.13388
- Targeting ALK in neuroendocrine tumors of the lung.Front Oncol. 2022; 12911294https://doi.org/10.3389/fonc.2022.911294
- Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.Cold Spring Harb Mol Case Stud. 2022; 8a006234https://doi.org/10.1101/mcs.a006234
- Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung.Cold Spring Harb Mol Case Stud. 2018; 4a002394https://doi.org/10.1101/mcs.a002394
- ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?.Per Med. 2018; 15: 111-115https://doi.org/10.2217/pme-2017-0069
- Alectinib re-challenge in small cell lung cancer transformation after chemotherapy failure in a patient with ALK-positive lung cancer: a case report.Respir Med Case Rep. 2021; 33101440https://doi.org/10.1016/j.rmcr.2021.101440
- ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: clinical and molecular description of two cases.Lung Cancer. 2020; 146: 350-354https://doi.org/10.1016/j.lungcan.2020.06.005
- Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma.Lung Cancer. 2016; 92: 15-18https://doi.org/10.1016/j.lungcan.2015.12.001
Published online: December 25, 2022
Accepted: December 11, 2022
Received in revised form: December 1, 2022
Received: October 1, 2022
Publication stageIn Press Journal Pre-Proof
© 2022 Elsevier Inc. All rights reserved.